Skip to content

Evaluation of robotic versus open partial pancreaticoduodenectomy – a randomised controlled trial (EUROPA)

Evaluation of robotic versus open partial pancreaticoduodenectomy – a randomised controlled trial (EUROPA) - EUROPA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00020407
Enrollment
80
Registered
2020-03-09
Start date
2020-06-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the pancreatic head requiring partial pancreatoduodenectomy C25.0 D37.70

Interventions

Group 1: robotic pancreatoduodenectomy (RPD) Group 2: open pancreatoduodenectomy (OPD)

Sponsors

Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Planned elective partial pancreaticoduodenectomy for any indication 2. Possibility to perform RPD and OPD as judged by the treating pancreatic surgeon 3. Age = 18 years 4. Ability of subject to understand character and individual consequences of the clinical trial 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Borderline or non-resectable carcinomas of the pancreatic head as defined by the National Comprehensive Cancer Network guidelines (1) 2. Distant metastases 3. American Society of Anaesthesiologists (ASA) Score >3 4. Participation in another interventional trial with interference of intervention and outcome of this trial 5. Expected lack of compliance or language problems

Design outcomes

Primary

MeasureTime frame
Overall postoperative morbidity in terms of the com-prehensive complication index (CCI) within 90 days after index operation.

Secondary

MeasureTime frame
- Feasibility of recruitment - Duration of surgery - Intraoperative blood loss - Serious adverse intraoperative events - Conversion rate in the robotic Group - Rate of a. microscopically complete margin clearance (>0.1cm margin clearance, R0(CRM-)) b. microscopic margin clearance =0.1cm (R0(CRM+)) c. microscopic margin involvement (R1) - Total number of resected lymph nodes and number of tumour-positive lymph nodes in patients with malignant tumours - Mortality within 90 days - Quality of recovery (QoR-15) - Time to functional recovery - Total length of intensive care unit stay within 90 days - Length of hospital stay for index Operation - Rate of superficial and deep surgical site infections (according to CDC) within 30 days - Rate and severity of postoperative pancreas specific complications (according to ISGPS and ISGLS): pancreatic fistula, postpancreatectomy haemorrhage, delayed gastric emptying, biliary leak, chyle leak within 90 days - Rate of non-surgical re-interventions within 90 days - Rate of re-operations within 90 days from index operation - Number of hospital re-admissions within 90 days. - Pain (Numeric Rating Scale) on postoperative day 1, 2 and 3 - Health-related quality of life measured by the SF-36 - Overall costs - Evaluation of surgeons’ mental workload/stress

Countries

Germany

Contacts

Public ContactThilo Hackert

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

thilo.hackert@med.uni-heidelberg.de06221-565150

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 16, 2026